The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company ...
Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.
Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...
People with ties to Brownstone Institute have significant authority over access to vaccines and scientific research.
AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on ...
MedPage Today on MSN
mRNA Flu Vaccine Tops Standard Shot in Trial
For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback